HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.366789-02-8
HENAN SUNLAKE ENTERPRISE CORPORATION
Our company advantages:
1、The highest quality with the competitive price.
2、Professional human services.
3、The fastest and safest delivery service.
4、The faster and safest delivery service.
5、The high purity products.
6、We have a sufficient supply of stock.
7、A variety of payments, such as L/C, TT, , MoneyGram or other payments.
Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion. The com[any was established in june. 1998, until now having more than 18 years experience in manufacturing & exporting chemical raw material .
Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others. These products have been being well exported to europe, southeast Asia, the Middle East ,Africa, South America and some other countries and areas.
We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team. We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional supplier in international market.
We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!
Rivaroxaban Basic information
| Antithrombotic drugs application |
| Product Name: | Rivaroxaban |
| Synonyms: | 5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide;BAY 59-7939;Rivaroxaban;5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide;2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl];Xarelto;(S)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide;Rivaroxaban (BAY59-7939) |
| CAS: | 366789-02-8 |
| MF: | C19H18ClN3O5S |
| MW: | 435.88 |
| EINECS: | |
| Product Categories: | Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;API;Inhibitor;Rivaroxaban;Pharmaceutical raw materials;Inhibitors |
| Mol File: | 366789-02-8.mol |
|
|
|
| Rivaroxaban Chemical Properties |
| mp | 228-229°C |
| storage temp. | Refrigerator |
| Safety Information |
| Rivaroxaban Usage And Synthesis |
| Antithrombotic drugs |
Rivaroxaban and dabigatran etexilate are currently the most promising antithrombotic drugs, and compared to traditional antithrombotic drugs heparin, essential difference is that it does not require participation of antithrombin Ⅲ, directly antagonizes the free and bound Xa factor. And heparin needs to have antithrombin Ⅲ and can play a role, and is invalid to the prothrombin complex of Xa factor. Two new oral anticoagulants are praised as as a major step forward of anticoagulant therapy and potentially fatal thrombosis prevention in the medical field, will become a new milestone in the development of cardiovascular drugs. Rivaroxaban was associated research and development success by the German Bayer and USA Johnson & Johnson. In October 2008, get approved for listing in Canada and the EU, trade name is Xarelto. Rivaroxaban is the world's first oral direct Xa factor inhibitor, can be high selectively, competitively inhibit free and bound Xa factor and activity of prothrombin, in a dose - dependent manner prolonged activated partial thromboplastin time board (PT) and prothrombin time (aPTT), thus prolonging the clotting time, reducing thrombin formation. Having characteristics of high bioavailability, a wide spectrum of disease treatment, dose effect relationship is stable, convenient oral administration, low bleeding risk. Rivaroxaban also is drug for prevention and treatment of venous thrombosis. Clinically for the prevention of forming patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip joint and knee replacement surgery. It can also be used to prevent stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation, reduce the risk of recurrent coronary syndrome, and so on. Dabigatran is a new antithrombotic drugs with a variety of characteristics developed by a German company Boehringer Ingelheim. In April 2008, first listed in Germany and the UK, Trade name was Pradaxa. This is listed first oral anticoagulant drug following warfarin in the past 50 years, is another milestone in the field of anticoagulant therapy and potentially fatal thrombosis prevention. Dabigatran is a new synthetic direct thrombin inhibitor, is a prodrug for oral administration, belongs to the thrombin inhibitors of non-peptides. After oral gastrointestinal absorption, it is converted to have a direct anticoagulant activity of dabigatran etexilate in vivo. Drug binds to the fibrin-specific binding sites of thrombin, preventing fibrinogen from cleaving into fibrin, thereby blocking the final step of the coagulation cascade network and thrombosis. The above information is edited by the chemicalbook of Liu Yujie. |
| application | For elective hip joint or knee replacement surgery in adult patients to prevent venous thrombosis (VTE). |
| Chemical Properties | White Solid |
| Usage | anti-coagulant, Factor X inhibitor |
| Usage | A novel antithrombotic agent. A highly potent and selective, direct FXa inhibitor |